NeuraStasis is developing an electrical stimulation device to delay the effects of acute ischemic stroke (AIS). The thesis behind this technology is that noninvasive electrical stimulation can preserve brain viability and help protect patients from a lifetime of disability. NeuraStasis’ initial addressable market focuses on AIS patients at stroke centers between diagnosis and revascularization. NeuraStasis reduces length of stay and long-term disability expenditure, providing significant value to providers and payers.